---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-007689"
form_type: "8-K"
ticker: "TMCI"
cik: "0001630627"
company_name: "TREACE MEDICAL CONCEPTS, INC."
filed_at: "2022-01-12T23:59:59+00:00"
generated_at: "2026-06-27T18:38:15.008548+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Treace Medical prelim Q4 rev $33.1-33.4M, FY rev $94.1-94.4M (+64-65% YoY)

## Summary
- Preliminary Q4 2021 revenue $33.1M-$33.4M (up 37-39% YoY); FY 2021 revenue $94.1M-$94.4M (up 64-65% YoY).
- Full-year revenue at high end of prior guidance range of $90M-$95M.
- Sequential Q4 revenue growth of 53-54% vs Q3 2021.
- CEO cites strength of direct sales channel, DTC, and surgeon training programs.
- Company to provide 2022 financial guidance on Q4 earnings call.

## SEC filing metadata
- accession: 0001193125-22-007689
- form_type: 8-K
- ticker: TMCI
- cik: 0001630627
- company_name: TREACE MEDICAL CONCEPTS, INC.
- filed_at: 2022-01-12T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1630627/000119312522007689/0001193125-22-007689-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1630627/000119312522007689/d264837d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-007689
- JSON: https://secwatch.observer/filing/0001193125-22-007689.json
- Plain text: https://secwatch.observer/filing/0001193125-22-007689.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.